Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.

Peter F Thall1, John D Cook, Elihu H Estey

  • 1Department of Biostatistics and Applied Mathematics, The University of Texas, MD Anderson Cancer Center, Houston, USA. rex@mdanderson.org

Journal of Biopharmaceutical Statistics
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Statistics in medicine·2026
Same author

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Precision generalized phase I-II designs.

Biometrics·2025
Same author

Practical Bayesian Guidelines for Small Randomized Oncology Trials.

Cancers·2025
Same author

Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

This study introduces an adaptive Bayesian method for clinical trials to find the optimal dose of experimental treatments. This outcome-adaptive approach balances treatment efficacy and toxicity for better patient outcomes in early-phase trials.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Conventional Phase I and Phase II trials have distinct objectives: dose escalation and efficacy assessment, respectively.
  • Integrating these phases can improve efficiency and patient outcomes in early drug development.
  • Adaptive designs allow for modifications based on accumulating data, enhancing trial responsiveness.

Purpose of the Study:

  • To describe and illustrate an outcome-adaptive Bayesian procedure for dose assignment in clinical trials.
  • To present a novel "Phase I-II" design that combines dose-finding and efficacy evaluation.
  • To provide a practical framework for determining the optimal experimental treatment dose for successive patient cohorts.

Main Methods:

  • Utilizes an outcome-adaptive Bayesian procedure proposed by Thall and Cook (2004).

Related Experiment Videos

  • Employs elicited (efficacy, toxicity) probability pairs to construct dose-desirability trade-off contours.
  • Applies a dose-finding algorithm to determine the best dose for each patient cohort.

    • Main Results:

    • A computer simulation study assessed the design's average behavior in a trial for acute myelogenous leukemia.
    • Demonstrated the practical application of the method through a cohort-by-cohort trial example.
    • The Bayesian approach provides a quantitative basis for dose selection, balancing efficacy and toxicity.

    Conclusions:

    • The described Phase I-II design offers an efficient approach to experimental treatment dose selection.
    • The outcome-adaptive Bayesian procedure effectively integrates dose-finding and efficacy assessment.
    • Implementation of this design can lead to more informative and responsive early-phase clinical trials.